Evaluation of efficacy and safety of human insulin (Novo) in the treatment of insulin-dependent diabetes mellitus: A double-blind, multicenter clinical trial

J. Karam, S. Brink, R. Clements, L. Miller, Philip Raskin

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The safety and efficacy of human insulin (Novo) were evaluated in a double-blind, parallel, multicenter trial in which 47 insulin-dependent diabetic patients were randomly divided into two equal groups and treated with either purified pork or human insulin (Actrapid and Monotard, Novo) for 12 wk. Mean levels of fasting plasma glucose, glycohemoglobin, and daily insulin dosages showed no statistical differences between the two groups, and there was no significant difference in the incidence of hypoglycemic reactions. The results from this clinical trial indicate that human insulin, prepared by enzymatic transpeptidation of pork insulin, appears to be as safe and efficacious as purified pork insulin in the treatment of insulin-dependent diabetes mellitus.

Original languageEnglish (US)
Pages (from-to)56-60
Number of pages5
JournalDiabetes Care
Volume6
Issue numberSuppl. 1
StatePublished - 1983

Fingerprint

Type 1 Diabetes Mellitus
Multicenter Studies
Clinical Trials
Insulin
Safety
Lente Insulin
Therapeutics
Hypoglycemic Agents
Fasting
Glucose
Incidence
Red Meat

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Evaluation of efficacy and safety of human insulin (Novo) in the treatment of insulin-dependent diabetes mellitus : A double-blind, multicenter clinical trial. / Karam, J.; Brink, S.; Clements, R.; Miller, L.; Raskin, Philip.

In: Diabetes Care, Vol. 6, No. Suppl. 1, 1983, p. 56-60.

Research output: Contribution to journalArticle

@article{2e7333574af44a7e9465244f0f10f5e6,
title = "Evaluation of efficacy and safety of human insulin (Novo) in the treatment of insulin-dependent diabetes mellitus: A double-blind, multicenter clinical trial",
abstract = "The safety and efficacy of human insulin (Novo) were evaluated in a double-blind, parallel, multicenter trial in which 47 insulin-dependent diabetic patients were randomly divided into two equal groups and treated with either purified pork or human insulin (Actrapid and Monotard, Novo) for 12 wk. Mean levels of fasting plasma glucose, glycohemoglobin, and daily insulin dosages showed no statistical differences between the two groups, and there was no significant difference in the incidence of hypoglycemic reactions. The results from this clinical trial indicate that human insulin, prepared by enzymatic transpeptidation of pork insulin, appears to be as safe and efficacious as purified pork insulin in the treatment of insulin-dependent diabetes mellitus.",
author = "J. Karam and S. Brink and R. Clements and L. Miller and Philip Raskin",
year = "1983",
language = "English (US)",
volume = "6",
pages = "56--60",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "Suppl. 1",

}

TY - JOUR

T1 - Evaluation of efficacy and safety of human insulin (Novo) in the treatment of insulin-dependent diabetes mellitus

T2 - A double-blind, multicenter clinical trial

AU - Karam, J.

AU - Brink, S.

AU - Clements, R.

AU - Miller, L.

AU - Raskin, Philip

PY - 1983

Y1 - 1983

N2 - The safety and efficacy of human insulin (Novo) were evaluated in a double-blind, parallel, multicenter trial in which 47 insulin-dependent diabetic patients were randomly divided into two equal groups and treated with either purified pork or human insulin (Actrapid and Monotard, Novo) for 12 wk. Mean levels of fasting plasma glucose, glycohemoglobin, and daily insulin dosages showed no statistical differences between the two groups, and there was no significant difference in the incidence of hypoglycemic reactions. The results from this clinical trial indicate that human insulin, prepared by enzymatic transpeptidation of pork insulin, appears to be as safe and efficacious as purified pork insulin in the treatment of insulin-dependent diabetes mellitus.

AB - The safety and efficacy of human insulin (Novo) were evaluated in a double-blind, parallel, multicenter trial in which 47 insulin-dependent diabetic patients were randomly divided into two equal groups and treated with either purified pork or human insulin (Actrapid and Monotard, Novo) for 12 wk. Mean levels of fasting plasma glucose, glycohemoglobin, and daily insulin dosages showed no statistical differences between the two groups, and there was no significant difference in the incidence of hypoglycemic reactions. The results from this clinical trial indicate that human insulin, prepared by enzymatic transpeptidation of pork insulin, appears to be as safe and efficacious as purified pork insulin in the treatment of insulin-dependent diabetes mellitus.

UR - http://www.scopus.com/inward/record.url?scp=0020660210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020660210&partnerID=8YFLogxK

M3 - Article

C2 - 6343041

AN - SCOPUS:0020660210

VL - 6

SP - 56

EP - 60

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - Suppl. 1

ER -